Australia Sues 3M for Over A$2 Billion Over PFAS Firefighting Foam Contamination 
Samsung Workers Approve Wage Deal, Avoiding Major Strike and Boosting Chip Supply Confidence 
Blue Origin New Glenn Rocket Explodes During Launch Pad Test, Delaying Space Ambitions 
Universal Music Group Rejects Pershing Square Takeover Proposal 
Costco Q3 Fiscal 2026 Earnings Beat Expectations as Sales and E-Commerce Surge 
US Quantum Stocks Surge After $2 Billion Government Investment 
Autodesk Beats Q1 Estimates, Acquires MaintainX for $3.6 Billion 
Snowflake Stock Soars 30% After Q1 Earnings Beat and Major AWS AI Partnership 
Samsung Union Dispute Escalates Over Semiconductor Bonus Vote 
Sable Offshore Wins Key Court Battle Over California Oil Pipeline 
SQM Q1 Profit More Than Doubles as Lithium Prices Surge 
Xiaomi Shares Drop After Weak Q1 Earnings Amid Rising Smartphone Costs 
Marvell Stock Rises After Record Q1 FY2027 Earnings Fueled by AI Demand 
HP Q2 2026 Earnings Beat Expectations Despite Memory Chip Pressure 
Kentucky School District Secures $27 Million in Social Media Addiction Lawsuit Settlements 
Meta Subscription Push Could Add Billions in Recurring Revenue, Says Rosenblatt 
Samsung to Invest $1.5 Billion in Vietnam Semiconductor Testing Plant by 2027 
Thermo Fisher Scientific Inc., a leading U.S.-based medical equipment manufacturer, is reportedly close to finalizing an all-cash acquisition of clinical trial data management company Clario in a deal valued at around $10 billion, according to the Financial Times. While Reuters has not yet confirmed the report, sources suggest the announcement could come as early as Wednesday, provided no last-minute complications arise.
If completed, this would mark Thermo Fisher’s largest acquisition since its $17.4 billion purchase of contract research organization PPD in 2021. The deal underscores Thermo Fisher’s strategic push to expand its footprint in clinical research and digital health data management, sectors that have seen accelerated growth in recent years.
Clario, established in 2021 through the merger of health tech companies ERT and Bioclinica, provides advanced software solutions that help pharmaceutical companies manage and analyze clinical trial data efficiently. The company’s investors include private equity firms Nordic Capital and Astorg. Clario’s technology plays a vital role in streamlining drug development processes, making it an attractive acquisition target amid growing demand for AI-driven healthcare solutions.
Neither Thermo Fisher nor Clario has commented on the reported deal. However, the acquisition aligns with Thermo Fisher’s ongoing strategy of strengthening its portfolio through high-value takeovers. Earlier in 2024, the company announced plans to acquire Solventum’s purification and filtration business for approximately $4.1 billion, further enhancing its capabilities in life sciences and laboratory technologies.
With increasing global demand for laboratory tools and integrated data solutions, Thermo Fisher recently raised its annual profit and revenue forecasts, signaling confidence in its growth trajectory. The potential Clario acquisition would not only expand Thermo Fisher’s reach in clinical research but also reinforce its position as a global leader in healthcare innovation and biotechnology.
